# US 2012/0252891 A1 · Vanilloid Fatty Hydroxamates as Therapeutic Anti-inflammatory Pharmaceuticals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252891 A1
- Document ID: US20120252891A1
- Status: Published application
- Kind: A1
- Application number: 13/422,565
- Filed: 2012-03-16
- Published: 2012-10-04
- Earliest claimed: 2011-03-16
- Assignees: University of Medicine and Dentistry of New Jersey; Lehigh University; Rutgers, The State University of New Jersey
- Inventors: Jeffrey D. Laskin; Ned D. Heindel; Carl Jeffrey Lacey; Abhilash N. Pillai; Marion Gordon; Diane E. Heck
- Web page: https://patentgrep.com/patent/US20120252891A1

## CPC

- C07C 271/16: to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- A61P 17/00: Drugs for dermatological disorders
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07C 259/06: having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Three unique subtypes of N-hydroxyamides and N-hydroxycarbamates containing both the vanilloid moiety (4-hydroxy-3-methoxybenzyl) and a lipophilic aliphatic moiety. Also disclosed are direct syntheses of these vanilloid fatty hydroxamates. The compounds possess inhibitory activity against the enzymes fatty acid amide hydrolase (FAAH) and matrix metallo-proteinase 9 (MMP-9). In addition, these substances bind to the calcium channel protein TRPV1 and inhibit vesicant-induced inflammation in skin and cornea. The compounds have utility in treating topical or systemic inflammatory processes in the skin and/or eye.

## Claims

### Claim 1

A vanilloid fatty N-hydroxy amide or vanilloid fatty N-hydroxy carbamate compound represented by Formula (V):
wherein R is a lipophilic moiety selected from the group consisting of linear and branched alkyl, optionally branched cycloalkyl, linear and branched alkenyl, optionally branched cycloalkenyl, linear and branched alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, and optionally substituted arylalkyl;
and wherein:
(1) X is NOH and Y is (C═O)O, or
(2) X is NOH and Y is C═O, or
(3) X is C═O and Y is NOH.

### Claim 2 (depends on 1)

The compound of claim 1, selected from the group consisting of alkyl-N-hydroxy-N-4-hydroxy-3-methoxybenzylcarbamates.

### Claim 3 (depends on 1)

The compound of claim 1, selected from the group consisting of N-hydroxy-N-4-hydroxy-3-methoxybenzylcarboxamides.

### Claim 4 (depends on 1)

The compound of claim 1, selected from the group consisting of N-hydroxy-N-alkyl-(4-hydroxy-3-methoxyphenyl)acetamides.

### Claim 5 (depends on 1)

The compound of claim 1 which is a prodrug or a salt a compound of Formula (V).

### Claim 6 (depends on 2)

A method for preparing a compound according to claim 2, comprising the step of reacting a benzylic hydroxylamine with a chloroformate in the presence of magnesium oxide to direct acylation onto the nitrogen atom of the hydroxylamine and thereby yield an alkyl-N-hydroxy-N-benzylcarbamate of formula

### Claim 7 (depends on 3)

A method for preparing a compound according to claim 3, comprising the step of reacting a benzylic hydroxylamine with an acylated 2-mercaptothiazoline to direct acyla-tion onto the nitrogen atom of the hydroxylamine and thereby yield an N-hydroxy-N-benzyl-carboxamide of formula

### Claim 8 (depends on 4)

A method for preparing a compound according to claim 4, comprising the steps of:
(a) condensing an aliphatic aldehyde with O-benzylhydroxylamine to form an oxime,
(b) reducing the oxime to an O-benzylhydroxylamine,
(c) condensing the O-benzylhydroxyamine with homovanillic acid (4-hydroxy-3-methoxyphenylacetic acid) to form an amide, and
(d) subjecting the amide to hydrogenolysis to cleave the O-benzyl group and thereby yield the N-hydroxy-N-alkyl(4-hydroxy-3-methoxyphenyl)acetamide of formula

### Claim 9 (depends on 1)

A method for treatment of a disease state which is influenced by the regulation of FAAH, comprising administering to a patient in need thereof an amount of a compound of claim 1 effective to inhibit fatty acid amide hydrolase (FAAH).

### Claim 10 (depends on 1)

A method for treatment of a disease state in which the regulation of MMP-9 is desired, comprising administering to a patient in need thereof an amount of a compound of claim 1 effective to inhibit matrix metalloproteinase-9 (MMP-9).

### Claim 11 (depends on 1)

A method for treatment of a disease state in which the regulation of an inflammatory response is desired, comprising administering to a patient in need thereof an amount of a compound of claim 1 effective to suppress one or more inflammatory responses.

### Claim 12 (depends on 1)

A method for treatment of a disease state in which inhibition of the separation of the ocular or cutaneous epithelium and stromal layers of the eye is desired, comprising administering to a patient in need thereof an amount of a compound of claim 1 effective to inhibit the separation of the ocular or cutaneous epithelium and stromal layers of the eye.

### Claim 13 (depends on 12)

The method of claim 12, wherein said compound is formulated as an ophthalmic solution and is applied topically via dropwise application to the eye.

### Claim 14 (depends on 1)

A method for treatment of a topical or systemic disease state in which inhibition of an inflammatory dysfunction is desired, comprising administering to a patient in need thereof an amount of a compound of claim 1 effective to modulate said inflammatory dysfunction, wherein the compound of claim 1 is formulated in a dosage form effective to deliver said compound to a desired site.

### Claim 15 (depends on 1)

A method for treatment of injury to skin and/or eyes produced by vesicating agents, corrosive chemicals, or damage-producing substances, comprising administering to a patient in need thereof an amount of a compound of claim 1 effective to function as an antagonist of the injury caused by vesicating agents, corrosive chemicals, or damage-producing substances, wherein said compound of claim 1 is optionally formulated.

### Claim 16 (depends on 1, 15)

The method of claim 15 for treatment of ocular injury produced by vesicating agents, corrosive chemicals, or damage-producing substances, comprising administering to a patient in need thereof an amount of a compound of claim 1 effective to relieve said ocular injury, wherein said compound of claim 1 is formulated as an ophthalmic solution and is applied topically via dropwise application to the eye.
